Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Glucocorticoid Use Associated with Serious Bacterial Blood Infection Risk

By LabMedica International staff writers
Posted on 21 Jun 2016
The risk of life-threatening blood infections by Staphylococcus aureus bacteria is more than doubled in users of systemic glucocorticoids compared with non-users and the risk escalates with increasing dose.

S. More...
aureus is a bacterium that normally lives harmlessly on the skin, but occasionally it causes infection, which can be fatal if the bacteria enter the bloodstream. Glucocorticoids are potent immunosuppressive drugs when given through the mouth or by injection and are used for treatment of many different medical conditions.

Scientists at the Aalborg University Hospitals (Denmark) and at Aarhus University Hospital (Denmark) and their German colleagues analyzed records of nearly 30,000 people using Danish medical registries over a 12-year period. The team investigated the risk of infection while taking into account duration of glucocorticoid use, 90-day cumulative dose, and specific groups of patients who are very frequently prescribed glucocorticoids.

The users of systemic glucocorticoids experienced a 2.5 times increased risk of S. aureus infection acquired outside of a hospital, as compared with non-users. The risk of infection rose gradually with increasing cumulative dose; compared with non-users. Patients with a 90-day cumulative dose of less than or equal to 150 mg were 2.4 times more at risk, rising to as high as 6.3 times greater risk among those with a cumulative dose of more than 1,000 mg. Among patients with connective tissue disease or chronic pulmonary disease, the risk of S. aureus blood infection was most pronounced in long-term users of glucocorticoids, whereas the risk was highest for new users among cancer patients.

Jesper Smit, MD, the lead author of the study, said, “Our study provides evidence that use of systemic glucocorticoids is associated with considerable risk of S. aureus blood infection, particularly among persons receiving high-dose therapy. These results may serve as a reminder for clinicians to weigh carefully the elevated risk against the potential beneficial effect of glucocorticoid therapy. This is especially pertinent in patients who are already vulnerable to infection.” The study was published on June 8, 2016, in the journal Mayo Clinic Proceedings.

Related Links:
Aalborg University Hospitals
Aarhus University Hospital

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.